The contract, though sizable, is likely immaterial to CVS’ earnings. But it moves the company in a positive direction as it ...

For 2025, Barclays estimates market forecasts include expectations of 110 basis points in Medicare margin expansion, which is on the lower end of CVS’s target range of 100-200 bps.

That shows the power of CVS’ market saturation; it pushed Hyrimoz through every arm of its business. CVS said the list price of Hyrimoz is 81% cheaper than brand-name Humira.

CVS Health Corp. is tapping the investment-grade corporate bond market on Tuesday, with a five-part deal that’s expected to price later in the day.

Barclays upgraded CVS Health Inc (NYSE:CVS) on higher Pharmacy & Consumer Wellness (PCW) estimates as headwinds are offset by share gains, with further upside potential from CostVantage. Despite ...